Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone replacement therapy and the bladder.

Keri S McCully1, Simon Jackson

  • 1Obstetrics and Gynaecology, Milton Keynes General Hospital, Milton Keynes MK6 5LD, UK.

The Journal of the British Menopause Society
|April 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal of lipid research·2026
Same author

Mobile colistin resistance in New Zealand without local agricultural colistin use: Genomic insights into mcr-carrying plasmids and their global context, 1984-2024.

International journal of antimicrobial agents·2026
Same author

Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy.

Science (New York, N.Y.)·2026
Same author

Integration of bla<sub>OXA-48</sub> into a Col156 plasmid drove a carbapenem-resistant Escherichia coli ST131 outbreak in New Zealand: Global genomic evidence for the gene's multilayered dissemination.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2025
Same author

Patient-Reported Long-Term Outcomes of Laparoscopic Sacrocolpopexy.

International urogynecology journal·2025
Same author

The early injected genomic region determines sensitivity to Type I restriction-modification defence against Autographiviridae phages.

Nucleic acids research·2025
Same journal

Mammographic density: a hormonally responsive risk factor for breast cancer.

The journal of the British Menopause Society·2006
Same journal

Reproductive ageing, sex steroids and depression.

The journal of the British Menopause Society·2006
Same journal

Controversies in the use of adjuvant trastuzumab (Herceptin).

The journal of the British Menopause Society·2006
Same journal

Health benefits of weight reduction in postmenopausal women: a systematic review.

The journal of the British Menopause Society·2006
Same journal

Cognitive function testing: the case for standardization and automation.

The journal of the British Menopause Society·2006
Same journal

Hysterectomy and sexual function.

The journal of the British Menopause Society·2006
See all related articles

Estrogen therapy can effectively treat urinary incontinence and reduce urinary tract infections in women. However, combining estrogen with progestogen may reduce its benefits, requiring further research.

Area of Science:

  • Gynecology
  • Urology
  • Gerontology

Background:

  • Lower urinary tract symptoms (LUTS) are prevalent in women, increasing with age.
  • Estrogen therapy has been used for LUTS, but its efficacy remains debated.
  • Epidemiological evidence on hormone replacement therapy for female LUTS requires critical review.

Purpose of the Study:

  • To critically review epidemiological evidence for hormone replacement therapy in treating women's urinary symptoms.
  • To assess the efficacy of estrogen preparations for managing urinary incontinence and infections.

Main Methods:

  • Systematic review of epidemiological studies on estrogen therapy for LUTS.
  • Analysis of data concerning stress incontinence, urge incontinence, and recurrent urinary tract infections.

Related Experiment Videos

Main Results:

  • Estrogen replacement demonstrates efficacy in improving or curing urinary stress and urge incontinence.
  • High-dose estrogen can decrease voiding frequency, including nocturnal voids.
  • Vaginal estriol significantly reduces recurrent urinary tract infections in postmenopausal women.

Conclusions:

  • Estrogen therapy is a viable option for managing female LUTS, including incontinence and recurrent UTIs.
  • Combined estrogen-progestogen therapy's role requires further investigation due to potentially negated benefits.
  • More research is needed to clarify the role of combined hormone therapy for urinary symptoms.